About
Dr. Sherif Salah Abdelaziz is a scientist, clinical pathology consultant, and pharmaceutical innovator with academic training in microbiology, immunology, clinical pathology, and bacteriology from Cairo University. He currently serves as Chief Executive Officer of DermaCure Pharmaceuticals and ASHMAN Pharmaceuticals, companies focused on biological therapeutics, dermatological preparations, and immunological therapies. His research interests include cancer, infectious diseases, autoimmune disorders, neurodegenerative diseases, diabetes, mitochondrial biology, immunometabolism, and translational drug develop
Skills & Expertise
Clinical Pathology
Microbiology
Immunology
Bacteriology
Pharmaceutical Innovation
Drug Discovery
Biological Therapeutics
Immunometabolic Modulation
Oncology Research
Diabetes Research
Molecular Biology
Mitochondrial Biology
Cell Culture
Animal Models
ELISA
PCR
qPCR
Histopathology
Immunohistochemistry
Patent Development
Scientific Writing
Regulatory Documentation
Research Project Management
Strategic Leadership
Pharmaceutical Product Development
Technology Transfer
Research Interests
No research interests added yet.
Connect With Me
Experience
Chief Executive Officer (CEO)
Leading the strategic direction, research and development, and pharmaceutical innovation programs of DermaCure Pharmaceuticals and ASHMAN Pharmaceuticals. Responsibilities include biologic drug development, dermatological and immunological product innovation, intellectual property management, regulatory strategy, technology transfer, and collaboration with academic and industrial partners.
Education
Cairo University
Projects
GLX10: Immunometabolic Therapy for Type 2 Diabetes Mellitus
Development of a novel immunometabolic biological therapy targeting mitochondrial dysfunction, chronic inflammation, and impaired glucose metabolism in Type 2 diabetes mellitus through preclinical animal and in vitro studies.
Conferences & Seminars (3)
Keystone Symposia Conference: Neuroinflammation in Diseases of the Central Nervous System
Invited to participate in the Keystone Symposia Conference on Neuroinflammation in Diseases of the Central Nervous System. Presented the accepted poster abstract entitled "A Novel Approach for Treatment of Patients with Multiple Sclerosis by Using DNA Polymerase." The conference brought together leading international researchers to discuss advances in neuroinflammation, neuroimmunology, and neurological diseases.
Alzheimer's Disease International Conference
Presented research on innovative therapeutic approaches for Alzheimer's disease and neurodegenerative disorders.
International Conference on HIV/AIDS
Invited speaker presenting innovative therapeutic approaches for Human Immunodeficiency Virus (HIV) infection and immunotherapy.
Certificates & Licenses (5)
Master of Science Certificate
Master of Science in Microbiology and Immunology.
Bachelor of Veterinary Medical Sciences
Bachelor of Veterinary Medical Sciences, Faculty of Veterinary Medicine.
Diploma in Diagnostic Microbiology
Postgraduate Diploma in Diagnostic Microbiology.
Diploma in Clinical Pathology
Postgraduate Diploma in Clinical Pathology.
Honorary Doctorate Certificate
Awarded an Honorary Doctorate in recognition of distinguished contributions to scientific research and pharmaceutical innovation.
Awards & Achievements (7)
🏆 Certificate of Appreciation
Awarded in recognition of distinguished scientific achievements and contributions to biomedical research.
🏆 Silver Medal for Scientific Innovation
Recognized for continued excellence in pharmaceutical innovation and biomedical research.
🏆 Silver Medal for Innovation
Awarded for innovative biomedical invention with international scientific significance.
🏆 Silver Medal for Scientific Innovation
Awarded for outstanding contribution to biomedical innovation and scientific research.
🏆 Gold Medal for Innovation
Awarded in recognition of excellence in pharmaceutical innovation and translational biomedical research.
Patents (5)
Novel Biological Enteric Dialysis Method For CKD And ESRD.
The present invention introduces novel composition in granules form to be used for enteric dialysis to eliminate toxins and other metabolic waste products, this composition consists of oral Ispaghula seed/husk in granules form coated with three types of polyclonal antibodies that adsorb uremic toxins and their precursors within the gastrointestinal tract, allowing them to be excreted in the feces preventing any progression of CKD.
A novel enzymes compositions for treatment of (HIV) infection
This invention relates to use bifunctional enzymes for display extremely broad spectrum neutralization antibodies
thus rendering it a potential effective antiviral agent against human immunodeficiency virus (HIV).
3- Novel treatment for autoimmune diseases
This patent describes a pharmaceutical composition containing biologically active molecules designed to treat multiple sclerosis, rheumatoid arthritis, and related inflammatory disorders by selectively blocking cytokine receptors and modulating inflammatory signaling pathways.
Anticancer therapeutic compositions for treatment of liver cancer
This patent describes an innovative therapeutic approach for cancer treatment based on restoring depleted intracellular polymerase enzyme activity while enhancing the host immune response against malignant cells. The composition combines biologically active enzyme therapy with monoclonal antibodies to promote immune-mediated recognition and elimination of cancer cells, providing a novel immunotherapeutic strategy for oncology.
Antiviral combination for treatment of HCV&HBV
This patent describes an innovative antiviral therapeutic composition designed for the treatment of Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) infections. The invention combines a synthetic amino acid with antifibrinolytic properties and two types of antibodies to provide a dual mechanism of action. The antibody components are intended to enhance host immune responses and interfere with viral immune-evasion mechanisms, while the synthetic amino acid is designed to protect fibrinogen from virus-associated effects. This integrated immunomodulatory approach represents a novel therapeutic strategy for managing chronic viral hepatitis.
Publications (8)
HIV pathogenesis is known to cause a progressive depilation of CD4+ T-cell cell population in close association with progressive impairment of cellular immunity and increase the susceptibility to infe...
Proposed a novel hypothesis that early hepatic fibrosis in hepatitis C functions as a protective defense mechanism to contain viral spread, providing a new perspective on disease pathogenesis and pote...
This study evaluates a novel antibody-functionalized psyllium granule formulation designed to bind and sequester uremic waste products, including urea, creatinine, and uric acid. Using serum samples f...
Developed a novel DNA polymerase–based therapeutic strategy for multiple sclerosis with potential immunomodulatory and disease-modifying effects.
Investigated the role of neutralizing antibodies and immune complexes in hepatitis C virus persistence and relapse, proposing a novel immunological mechanism and diagnostic approach.
dd